Chiaradonna Ferdinando, PhD

Keywords
Basis of cancer, signal transduction, cell cycle, cell death, cancer metabolism, relationship between cell metabolism and cancer hallmarks, tumor metabolism inhibition, systems biology

Research interest

Role of metabolism in tumor growth, maintenance and resistance to chemotherapy

The activity is focused on the following research lines
Health research area BtBs UNIMIB
Health

Cancer, Drug Discovery and Pharmacology, Systems biology

Graphical abstract
graphical-abstract-Ferdinando-Chiaradonna-BtBs-UNIMIB

Research Group

Barbara Zerbato - Fellowship
lab 5048, building U4, tel. +39 02 6448 3558, barbara.zerbato@unimib.it

Kirthana Porchera - Master student
lab 5048, building U4, tel. +39 02 6448 3558, k.porchera@campus.unimib.it

Maximilian Gobbi – Master student
lab 5048, building U4, tel. +39 02 6448 3558, m.gobbi5@campus.unimib.it

Research projects

2109-2021: Executive Programme of Scientific Collaboration between Italy and China, Innovative Biomedical Devices (BIOMED) 2019-2021 (Responsabile di Progetto), Preclinical evaluation of a PGM3 inhibitor as innovative therapeutic approach for pancreatic ductal adenocarcinoma finanziato dal Ministero Affari Esteri e Cooperazione Internazionale. Validazione preclinica in tumori pancreatici di un nuovo inibitore specifico della via delle esosammine e valutazione della sua capacità di inibire la resistenza dei tumori pancreatici alla gemcitabina.

Selected articles

-Ricciardiello F, Bergamaschi L, De Vitto H, Gang Y, Zhang T, Palorini R, Chiaradonna F. Suppression of the HBP function increases pancreatic cancer cell sensitivity to a pan-RAS inhibitor. Cells. 2021 Feb 18;10(2):431. DOI: 10.3390/cells10020431

-Ricciardiello F, Gang Y, Palorini R, Li Q, Giampà M, Zhao F, You L, La Ferla B, De Vitto H, Guan W, Gu J, Zhang T, Zhao Y, Chiaradonna F. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. Oncogene. 2020 May;39(20):4103-4117. DOI: 10.1038/s41388-020-1260-1

-Ghilardi C, Moreira-Barbosa C, Brunelli L, Ostano P, Panini N, Lupi M, Anastasia A, Fiordaliso F, Salio M, Formenti L, Russo M, Arrigoni E, Chiaradonna F, Chiorino G, Draetta G, Marszalek JR, Vellano CP, Pastorelli R, Bani MR, Decio A and Giavazzi R. PGC1α/β expression predicts the therapeutic response to oxphos inhibition in ovarian cancer. Cancer Res. 2022 Feb 7. DOI: 10.1158/0008-5472.CAN-21-1223

-Chiaradonna F, Ricciardiello F, Palorini R. The Nutrient-Sensing Hexosamine Biosynthetic Pathway as the Hub of Cancer Metabolic Rewiring. Chiaradonna F, Ricciardiello F, Palorini R. Cells. 2018 Jun 2;7(6).  DOI: 10.3390/cells7060053

International and national collaborations

- Prof. Taiping Zhang, Peking Union Medical College Hospital, Beijing, China; Institute of Materia Medica, Chinese Academy of medical Science, Beijing, China.

- Susanna Chiocca, Principal Investigator at European Institute of Oncology , Milan, Italy

- Alfonso Urbanucci, Principal Investigator at Institute for Cancer Research at Oslo University Hospital, Finland

- Andre Wegner, group leader of Pathometabolism group at BRICS (Braunschweig Integrated Centre of Systems Biology), University of Braunschweig, Germany

- Silvia Arpicco, Principal Investigator, Department of Drug Science and Technology, University of Turin, Italy

- Cuda Giovanni (Head of the Research Center of Biochemistry and Advanced Molecular Biology) and Domenica Scumaci (Responsible of Proteomic Lab), Department of Experimental and Clinical Medicine, University of Magna Graecia, Catanzaro

- Bodo Grimbacher (Scientific Director) and Miche Proietti (Head CCI Genetic and Genomic Unit), Medical Center - University of Freiburg, Center for Chronic Immunodeficiency at Center for Translational Cell Research, Freiburg, Germany


Chiaradonna’s Lab – #ChiaradonnaLab_BtBs
last update: November 2021